Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
TKM-Ebola (TKM-100201) (formerly Ebola SNALP)
print preview
bookmark
share with colleague
General Information
Company
Tekmira Pharmaceuticals Corp.
Description
Combination of short interfering RNAs (siRNAs) targeting Zaire Ebola L polymerase, Zaire Ebola membrane-associated protein (VP24) and Zaire Ebola polymerase complex protein (VP35) formulated with Tekmira's lipid nanoparticle (LNP) technology
Molecular Target
Mechanism of Action
Latest Stage of Development
Phase I
Indication
Ebola
Partner
Alnylam Pharmaceuticals Inc.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy